Stock Taper
SCREENER COMPARE ANY 2 STOCKS
PLRX
PLIANT THERAPEUTICS, INC.
NASDAQ
$1.16
▲ UP 2.65% (0.03)

KEY STATISTICS

Market Cap$71.83 M
52w High$1.95
52w Low$1.02
Dividend Yield—
Frequency—
P/E-0.79
Volume559.79K
Shares Out.61.92M

COMPANY

LEADERSHIP

Bernard Coulie
CHIEF EXECUTIVE
Bernard Coulie

COMPENSATION 2026

Salary$682,000
Stock Awards$1,810,250
Incentive Plan Pay$204,600
All Other Comp.$52,301
Total$5,462,901

ABOUT

SECTOR
Healthcare
WENT PUBLIC
June 3, 2020
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
49

PRICE TARGET

Target High$3.00
Target Low$3.00
Target Median$3.00
Target Consensus$3.00

UPCOMING EARNINGS

DateNov 5, 2026
DayThursday
Rev. Est.—
NOV
5
THU

PRICE

$1.16 ▲ UP 2.65% (+$0.03)
$1.12$1.14$1.169:30 AM10:35 AM11:40 AM12:44 PM1:49 PM2:54 PM3:59 PM1.16

About Pliant Therapeutics, Inc.

https://pliantrx.com ↗

Pliant Therapeutics, Inc. is a South San Francisco-based clinical-stage biopharmaceutical company developing novel therapies, including integrin inhibitors, for fibrosis, liver disease, oncology, and muscular dystrophies.

INDUSTRY

Biotechnology

A PRODUCT PLIANT THERAPEUTICS, INC. IS KNOWN FOR

Bexotegrast (PLN-74809)
Bexotegrast (PLN-74809)

The company's lead small molecule inhibitor targeting αvβ6 and αvβ1 integrins is in late-stage clinical development for IPF and fibrotic diseases, addressing the biological drivers of fibrosis.

COMPETITORS

COMPETITOR
CRBP COMPARE
UTHR COMPARE

ETFS HOLDING THIS STOCK

ETFS HOLDING
14
LISTED HERE
3
RANKED BY POSITION SIZE
VTI
0.00% · 1.7M
IWC
0.02% · 205.2K
PRFZ
0.00% · 104.3K

INSTITUTIONAL OWNERSHIP

SHARES OWNED
69.04%
HOLDERS
139
TOP 12 OF 139 · RANKED BY POSITION SIZE
Tang Capital Management LLC
6.1M sh · $7.74M
Blackrock Inc.
5.0M sh · $53.45M
Woodline Partners LP
4.5M sh · $6.67M
Point72 Asset Management, L.P.
4.3M sh · $6.42M
Morgan Stanley
3.5M sh · $5.19M
Citadel Advisors LLC
3.2M sh · $4.07M
Chi Advisors LLC
3.0M sh · $52.27M
Blue Owl Capital Holdings LP
3.0M sh · $4.39M
Vanguard Group Inc
2.8M sh · $3.44M
Adar1 Capital Management, LLC
2.6M sh · $3.26M
Acadian Asset Management LLC
2.4M sh · $3.04M
Two Sigma Investments, LP
2.3M sh · $2.84M

RATINGS SNAPSHOT

Overall rating: B-

DCFROEROAD/EP/EP/B
Discounted Cash Flow3
Return On Equity1
Return On Assets1
Debt To Equity3
Price To Earnings1
Price To Book5
Overall Score2

INSIDER TRADES

★
DIRECTOR
Borellini Flavia
Purchase · 60.0K shares
2026-07-09
★
DIRECTOR:
Borellini Flavia
— · —
2026-07-09
★
DIRECTOR:
Iannone Robert
— · —
2026-07-09
★
DIRECTOR
Iannone Robert
Purchase · 60.0K shares
2026-07-09

MOST RECENT ANALYST GRADES

GRADE SUMMARY
HOLD 1
OVERWEIGHT 1
SECTOR PERFORM 1
UNDERWEIGHT 1
4 GRADES IN THE LAST 12 MONTHS
Canaccord Genuity HOLD Piper Sandler OVERWEIGHT RBC Capital SECTOR PERFORM JP Morgan UNDERWEIGHT

SECTORS PEERS

PEERPRICE
ARTV$11.19COMPARE
OVID$2.80COMPARE
ZNTL$3.99COMPARE
MGNX$4.40COMPARE
WHWK$4.60COMPARE
STRO$20.07COMPARE
COYA$4.76COMPARE
GUTS$0.70COMPARE